» Articles » PMID: 16809941

Expression of Oct4, a Stem Cell Marker, in the Hamster Pancreatic Cancer Model

Overview
Journal Pancreatology
Date 2006 Jul 1
PMID 16809941
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Oct4 has been shown to present a stem cell marker that is expressed in embryonic cells and in germ cell tumors. Recently, its expression in a few human tissues and cancer cells has been reported. Because in the hamster pancreatic cancer model most tumors develop from within islets presumably from stem cells, we investigated the expression of Oct4 in this model.

Methods: Two normal pancreases and 15 pancreatic cancers induced by N-nitrosobis(2-oxypropyl)amine (BOP) were processed for immunohistochemistry using a monoclonal Oct4 antibody at a concentration of 1:500.

Results: In the normal pancreas, Oct4 was expressed only in islet cells in a diffuse cytoplasmic pattern. No nuclear staining was found in any cells. In 14 of the pancreatic cancers, nuclear staining was detected in many cells or in small foci. Diffuse cytoplasmic but no nuclear staining was found in one tumor and a mixed Golgi type and nuclear staining in two cases. Nuclear staining was also identified in early intrainsular ductular and in Ca in situ lesions.

Conclusions: BOP reactivates the Oct4 gene and can be considered an early tumor marker in this model.

Citing Articles

Research progress on FSH-FSHR signaling in the pathogenesis of non-reproductive diseases.

Li C, Ling Y, Kuang H Front Cell Dev Biol. 2024; 12:1506450.

PMID: 39633710 PMC: 11615068. DOI: 10.3389/fcell.2024.1506450.


Initiation of Cancer: The Journey From Mutations in Somatic Cells to Epigenetic Changes in Tissue-resident VSELs.

Bhartiya D, Raouf S, Pansare K, Tripathi A, Tripathi A Stem Cell Rev Rep. 2024; 20(4):857-880.

PMID: 38457060 DOI: 10.1007/s12015-024-10694-7.


OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy.

Ma Y Oncol Lett. 2023; 26(4):452.

PMID: 37720669 PMC: 10502952. DOI: 10.3892/ol.2023.14039.


OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer.

Liu T, Sun B, Zhao X, Li Y, Gu Q, Dong X Int J Mol Sci. 2014; 15(11):19634-49.

PMID: 25353179 PMC: 4264130. DOI: 10.3390/ijms151119634.


MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4.

Gao L, Yang Y, Xu H, Liu R, Li D, Hong H Tumour Biol. 2014; 35(8):8309-18.

PMID: 24859837 DOI: 10.1007/s13277-014-2092-9.